In brief: Epitan; Genesis R&D
Monday, 07 March, 2005
Epitan (ASX:EPT) has been given the green light to go ahead with its Phase II study evaluating the photo-protective effects of its sustained release formulation of Melanotan, after receiving ethics approval from the Royal Prince Alfred Hospital in Sydney.
The trial, which will be one of the last to complete before the company moves on to Phase III trials, is expected to start in April and take six months to complete. The RPA's Prof Ross Barnetson will be principal investigator for the study.
New Zealand biotech Genesis R&D (ASX/NZSX:GEN) has announced a legal dispute with a company it set up as a joint venture in 2000. The company, ArborGen, is developing elite transgenic trees for forestry. It has commenced proceedings including clarification of IP ownership and unspecified damages, and has requested that Genesis leaves the partnership. Genesis, through its subsidiary AgriGenesis, holds five per cent equity in the partnership, and has supplied ArborGen with technology and research services.
Link between oestrogen and heart health found in women
Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
